Mazin, I.; Chernomordik, F.; Fefer, P.; Matetzky, S.; Beigel, R.
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. J. Clin. Med. 2022, 11, 1904.
https://doi.org/10.3390/jcm11071904
AMA Style
Mazin I, Chernomordik F, Fefer P, Matetzky S, Beigel R.
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine. 2022; 11(7):1904.
https://doi.org/10.3390/jcm11071904
Chicago/Turabian Style
Mazin, Israel, Fernando Chernomordik, Paul Fefer, Shlomi Matetzky, and Roy Beigel.
2022. "The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients" Journal of Clinical Medicine 11, no. 7: 1904.
https://doi.org/10.3390/jcm11071904
APA Style
Mazin, I., Chernomordik, F., Fefer, P., Matetzky, S., & Beigel, R.
(2022). The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 11(7), 1904.
https://doi.org/10.3390/jcm11071904